Trump Announces Weight-Loss Drug Deal With Pharma in WH Event Marked by Scary Medical Issue

AP Photo/Evan Vucci

Donald Trump announced Thursday in the Oval Office that he’s struck a deal with two major pharmaceutical companies, Eli Lilly and Novo Nordisk, to lower prices for their popular weight-loss drugs, a new generation of products known as GLP-1 receptor agonists. The drugs, including Ozempic and Mounjaro, have proven very effective in helping people lose the pounds.

Advertisement

The event had a scary moment, however, when a pharmaceutical executive appeared to lose consciousness, and Dr. Mehmet Oz, the administration’s Administrator of the Centers for Medicare & Medicaid Services (CMS), had to rush to his aid.

Watch:

White House Press Secretary Karoline Leavitt later announced that the man – whose identity has been under dispute in the media - was expected to be “okay.” It’s unclear what caused the incident.

Regarding the deal concerning weight-loss drugs, meanwhile, the president said it would help millions of people:

The administration has recently been hinting that they’re going to be focusing their efforts on affordability going forward, and they say this is a step in that direction:

"[It] will save lives, improve the health of millions and millions of Americans," said Trump, in an Oval Office announcement in which he referred to GLP-1s as a "fat drug."

Thursday's announcement is the latest attempt by the Trump administration to rein in soaring drug prices in its efforts to address cost-of-living concerns among voters. Drugmakers Pfizer and AstraZeneca recently agreed to lower the cost of prescription drugs for Medicaid after an executive order in May set a deadline for drugmakers to electively lower prices or face new limits on what the government will pay.

Advertisement

MORE: Trump Administration Announcing Deal on Lowering Cost, Access on Fertility Treatments, IVF

Trump Admin Found 'More Than $1B' in Taxpayer Dollars Were Spent on Illegals' Healthcare


Here are some highlights about the deal:

President Donald Trump announced deals with Eli Lilly and Novo Nordisk to slash the prices of some of their obesity drugs, including upcoming pills, in a landmark effort to expand access to the costly blockbuster treatments. 

The agreements will lower prices of GLP-1 drugs on Medicare and Medicaid and offer the treatments directly to consumers at a discount on a website the Trump administration is launching in January 2026 called TrumpRx.gov.

The deals are among the most politically significant announcements to date in the Trump administration’s efforts to rein in high U.S. drug costs by tying them to the lowest prices abroad.

GLP-1 receptor agonists work by affecting hormones that regulate your appetite and insulin. They have proven to be extremely effective in helping people shed the pounds, but the cost is out of reach for a huge number of folks who would like to give them a try:

Obesity drugs’ popularity soars amid cost barriers

Zepbound and Wegovy belong to a class of treatments known as GLP-1 receptor agonists, which mimic natural hormones that regulate appetite and feelings of fullness. Clinical trials show the drugs can help patients lose between 15% and 22% of their body weight—often more than 50 pounds.

Despite their success, access has been limited. The treatments can cost around $500 a month for higher doses, and insurance coverage has been inconsistent. Until now, Medicare had covered the drugs only for conditions like type 2 diabetes or heart disease, not for obesity itself.

Advertisement

If your neighbor suddenly looks a lot more svelte next year, now you know one potential reason why.

Editor’s Note: The Schumer Shutdown is here. Rather than put the American people first, Chuck Schumer and the radical Democrats forced a government shutdown for healthcare for illegals. They own this.

Help us continue to report the truth about the Schumer Shutdown. Use promo code POTUS47 to get 74% off your VIP membership.

Recommended

Join the conversation as a VIP Member

Trending on RedState Videos